These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37885809)

  • 1. Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC.
    Terashima Y; Matsumoto M; Iida H; Takashima S; Fukuizumi A; Takeuchi S; Miyanaga A; Terasaki Y; Kasahara K; Seike M
    JTO Clin Res Rep; 2023 Nov; 4(11):100578. PubMed ID: 37885809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer.
    Nakao A; Inoue H; Ikeuchi N; Igata F; Aoyama T; Hamasaki M; Arima H; Fujita M
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
    Ibusuki R; Yoneshima Y; Hashisako M; Matsuo N; Harada T; Tsuchiya-Kawano Y; Kishimoto J; Ota K; Shiraishi Y; Iwama E; Tanaka K; Oda Y; Okamoto I
    Transl Lung Cancer Res; 2022 Nov; 11(11):2208-2215. PubMed ID: 36519019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
    Katayama Y; Yamada T; Morimoto K; Fujii H; Morita S; Tanimura K; Takeda T; Okada A; Shiotsu S; Chihara Y; Hiranuma O; Yamada T; Ota T; Harada T; Hasegawa I; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
    JTO Clin Res Rep; 2023 Apr; 4(4):100494. PubMed ID: 37020925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.
    Xiao HQ; Tian RH; Zhang ZH; Du KQ; Ni YM
    Onco Targets Ther; 2016; 9():1471-6. PubMed ID: 27042115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study.
    Mori S; Maiguma T; Yoshii K; Moriya Y; Takada R; Shinkai F; Haruki Y; Hashimoto H; Komoto A; Takayanagi K; Tamura K; Okura Y; Sugiyama T; Shimada K
    Am J Cancer Res; 2024; 14(8):3852-3858. PubMed ID: 39267683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.
    Iso H; Hisakane K; Mikami E; Suzuki T; Matsuki S; Atsumi K; Nagata K; Seike M; Hirose T
    Transl Lung Cancer Res; 2023 Sep; 12(9):1850-1861. PubMed ID: 37854151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
    J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
    Yang Y; Sun J; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Ma R; Bi M; Ren X; Zhou J; Li B; Song Y; Feng J; Li J; He Z; Zhou R; Li W; Lu Y; Zhou H; Wang S; Sun L; Puig O; Mancao C; Peng B; Fang W; Xu W; Zhang L
    J Thorac Oncol; 2021 Dec; 16(12):2109-2120. PubMed ID: 34358724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
    Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
    Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.
    Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL
    J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189.
    Gadgeel S; Gray JE; Rizzo MT; Peterson P; Kim JS; Rodríguez-Abreu D
    JTO Clin Res Rep; 2022 Nov; 3(11):100389. PubMed ID: 36406000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
    Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
    Nakahama K; Kaneda H; Osawa M; Izumi M; Yoshimoto N; Sugimoto A; Nagamine H; Ogawa K; Matsumoto Y; Sawa K; Tani Y; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
    Thorac Cancer; 2022 Aug; 13(16):2309-2317. PubMed ID: 35808895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
    Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
    Health Qual Life Outcomes; 2017 Aug; 15(1):160. PubMed ID: 28806963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
    Yang Y; Wang Z; Fang J; Yu Q; Han B; Cang S; Chen G; Mei X; Yang Z; Ma R; Bi M; Ren X; Zhou J; Li B; Song Y; Feng J; Li J; He Z; Zhou R; Li W; Lu Y; Wang Y; Wang L; Yang N; Zhang Y; Yu Z; Zhao Y; Xie C; Cheng Y; Zhou H; Wang S; Zhu D; Zhang W; Zhang L
    J Thorac Oncol; 2020 Oct; 15(10):1636-1646. PubMed ID: 32781263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.